$233.90 Million in Sales Expected for Evolent Health Inc (NYSE:EVH) This Quarter

Wall Street brokerages predict that Evolent Health Inc (NYSE:EVH) will announce sales of $233.90 million for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Evolent Health’s earnings, with estimates ranging from $229.70 million to $237.40 million. Evolent Health posted sales of $193.32 million in the same quarter last year, which indicates a positive year over year growth rate of 21%. The business is scheduled to report its next quarterly earnings results on Tuesday, February 25th.

On average, analysts expect that Evolent Health will report full-year sales of $844.46 million for the current financial year, with estimates ranging from $840.40 million to $847.20 million. For the next fiscal year, analysts expect that the company will report sales of $946.95 million, with estimates ranging from $888.50 million to $1.01 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Evolent Health.

Evolent Health (NYSE:EVH) last issued its earnings results on Tuesday, November 5th. The technology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.03. Evolent Health had a negative net margin of 15.02% and a negative return on equity of 6.93%. The company had revenue of $220.14 million during the quarter, compared to analysts’ expectations of $217.90 million. During the same period last year, the company posted ($0.04) earnings per share. The firm’s quarterly revenue was up 46.8% compared to the same quarter last year.

A number of research analysts have issued reports on EVH shares. Cowen set a $18.00 target price on shares of Evolent Health and gave the company a “buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald set a $16.00 target price on shares of Evolent Health and gave the company an “overweight” rating in a report on Wednesday, August 7th. ValuEngine raised shares of Evolent Health from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Piper Jaffray Companies increased their target price on shares of Evolent Health from $10.00 to $12.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Finally, Zacks Investment Research lowered shares of Evolent Health from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Evolent Health presently has an average rating of “Buy” and an average price target of $15.75.

Evolent Health stock traded up $0.39 during mid-day trading on Wednesday, reaching $9.50. The company had a trading volume of 1,210,589 shares, compared to its average volume of 1,101,149. Evolent Health has a 1 year low of $5.50 and a 1 year high of $26.96. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.19 and a quick ratio of 1.19. The company has a market capitalization of $778.41 million, a P/E ratio of -27.14 and a beta of 1.07. The stock’s 50-day simple moving average is $7.78 and its 200-day simple moving average is $8.67.

Several hedge funds have recently added to or reduced their stakes in EVH. Aperio Group LLC acquired a new stake in shares of Evolent Health in the second quarter valued at approximately $40,000. ETRADE Capital Management LLC acquired a new stake in shares of Evolent Health in the second quarter valued at approximately $80,000. DekaBank Deutsche Girozentrale grew its position in shares of Evolent Health by 94.4% in the second quarter. DekaBank Deutsche Girozentrale now owns 12,061 shares of the technology company’s stock valued at $95,000 after purchasing an additional 5,856 shares during the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. grew its position in shares of Evolent Health by 38.4% in the second quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 15,500 shares of the technology company’s stock valued at $123,000 after purchasing an additional 4,300 shares during the last quarter. Finally, NumerixS Investment Technologies Inc acquired a new stake in shares of Evolent Health in the second quarter valued at approximately $125,000. Institutional investors and hedge funds own 98.41% of the company’s stock.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Featured Article: Dividend Stocks – Are They Right For You?

Get a free copy of the Zacks research report on Evolent Health (EVH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.